Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Multi-center Study of SC411 for Sickle Cell Disease

NCT02604368 is registered in ClinicalTrials.gov with Micelle BioPharma Inc as lead sponsor.

NCT NCT02604368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02604368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Multi-center Study of SC411 for Sickle Cell Disease
Lead sponsor
Micelle BioPharma Inc
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2019
Completion date
December 31, 2020
Enrollment
210 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease